Western Blot (WB)
(Figure 1 Western Blot Validation in Human Cell LinesLoading: 15 μg of lysates per lane.Antibodies: DR4 1139 (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.Lane A: HepG2 cell lysateLane B: Jurkat cell lysate)
Rabbit anti-Human DR4 Polyclonal Antibody | anti-TNFRSF10A antibody
DR4 Antibody
Western Blot (WB)
(Figure 1 Western Blot Validation in Human Cell LinesLoading: 15 μg of lysates per lane.Antibodies: DR4 1139 (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.Lane A: HepG2 cell lysateLane B: Jurkat cell lysate)
Western Blot (WB)
(Figure 1 Western Blot Validation in Human Cell LinesLoading: 15 μg of lysates per lane.Antibodies: DR4 1139 (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.Lane A: HepG2 cell lysateLane B: Jurkat cell lysate)
Western Blot (WB)
(Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile in Cell LinesLoading: 15 μg of lysates per lane.Antibodies: DR4 1139 (1 μg/mL), DR4 1167 ( 4 μg/mL), and beta-actin (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.)
Western Blot (WB)
(Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile in Cell LinesLoading: 15 μg of lysates per lane.Antibodies: DR4 1139 (1 μg/mL), DR4 1167 ( 4 μg/mL), and beta-actin (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.)
Immunofluorescence (IF)
(Figure 3 Immunofluorescence Validation of DR4Immunofluorescent analysis of 4% paraformaldehyde-fixed human spleen tissue labeling DR4 with 1139 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue). Image showing membrane staining on human spleen cells.)
Immunofluorescence (IF)
(Figure 3 Immunofluorescence Validation of DR4Immunofluorescent analysis of 4% paraformaldehyde-fixed human spleen tissue labeling DR4 with 1139 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue). Image showing membrane staining on human spleen cells.)
Immunocytochemistry (ICC)
(Figure 4 Immunocytochemistry Validation of DR4Immunocytochemical analysis of 4% paraformaldehyde-fixed Jurkat cells labeling DR4 with 1139 at 10 μg/ml, followed by goat anti-rabbit IgG secondary antibody at 1/250 dilution (red). Image showing membrane staining on Jurkat cells.)
Immunocytochemistry (ICC)
(Figure 4 Immunocytochemistry Validation of DR4Immunocytochemical analysis of 4% paraformaldehyde-fixed Jurkat cells labeling DR4 with 1139 at 10 μg/ml, followed by goat anti-rabbit IgG secondary antibody at 1/250 dilution (red). Image showing membrane staining on Jurkat cells.)
Immunohistochemistry (IHC)
(Figure 5 Immunohistochemistry Validation of DR4Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti-DR4 antibody (1139) at 10 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚ C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.)
Immunohistochemistry (IHC)
(Figure 5 Immunohistochemistry Validation of DR4Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti-DR4 antibody (1139) at 10 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚ C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.)
Western Blot (WB)
(Figure 6 KD Validation in SW480 cells (Goda et al., 2008)The expression of DR4 was knocked down via DR4 siRNA, 24 h latercells were treated with dipyridamole for 24 h. DR4 protein expression detected by anti-DR4 antibodies (1139) was disrupted. Dipyridamole up-regulated the expression of DR4.)
Western Blot (WB)
(Figure 6 KD Validation in SW480 cells (Goda et al., 2008)The expression of DR4 was knocked down via DR4 siRNA, 24 h latercells were treated with dipyridamole for 24 h. DR4 protein expression detected by anti-DR4 antibodies (1139) was disrupted. Dipyridamole up-regulated the expression of DR4.)
Immunofluorescence (IF)
(Figure 7 Immunofluorescence Validation of DR4 in rat brain (Cantarella et al., 2014)DR4 protein expression detected by anti-DR4 antibodies (1139) was increased after transient brain ischemia (tMCAO) and decreased after pre-conditioning stimulus. Confocal microscopic images displaying NeuN (a,d, g) (green), DR4 (b, e, h) (red), and Merge (c, f, i) (yellow) in the brain peri-ischemic region of rats after 5 h.)
Immunofluorescence (IF)
(Figure 7 Immunofluorescence Validation of DR4 in rat brain (Cantarella et al., 2014)DR4 protein expression detected by anti-DR4 antibodies (1139) was increased after transient brain ischemia (tMCAO) and decreased after pre-conditioning stimulus. Confocal microscopic images displaying NeuN (a,d, g) (green), DR4 (b, e, h) (red), and Merge (c, f, i) (yellow) in the brain peri-ischemic region of rats after 5 h.)
Immunocytochemistry (ICC)
(Figure 8 Immunocytochemistry Validation of DR4 in human melanoma cells (Ekmekcioglu et al., 2008)MeWo melanoma cells were exposed to affinity-purified MDA7/IL-24. After 48 h of treatment, cells were collected and cytospins prepared for cytochemical assessment of their TRAIL receptor (R1 and R2) expression (anti-DR4 (1139) or anti-DR5, AEC, hematoxylin). Both DR4 and DR5 expression were upregulated in MeWo cells after treatment.)
Immunocytochemistry (ICC)
(Figure 8 Immunocytochemistry Validation of DR4 in human melanoma cells (Ekmekcioglu et al., 2008)MeWo melanoma cells were exposed to affinity-purified MDA7/IL-24. After 48 h of treatment, cells were collected and cytospins prepared for cytochemical assessment of their TRAIL receptor (R1 and R2) expression (anti-DR4 (1139) or anti-DR5, AEC, hematoxylin). Both DR4 and DR5 expression were upregulated in MeWo cells after treatment.)
Western Blot (WB)
(Figure 9 KD Validation in Huh7 cells (Malhi et al., 2007)Western blot analysis with anti-DR4 antibodies (1139) was performed for DR5 and DR4 expression using whole cell lysates from Huh 7 cells transfected with respective siRNAs. In cells treated with siDR4, a decrease in DR4 level was observed, DR5 levels were unchanged. Scrambled siRNA was used as control.)
Western Blot (WB)
(Figure 9 KD Validation in Huh7 cells (Malhi et al., 2007)Western blot analysis with anti-DR4 antibodies (1139) was performed for DR5 and DR4 expression using whole cell lysates from Huh 7 cells transfected with respective siRNAs. In cells treated with siDR4, a decrease in DR4 level was observed, DR5 levels were unchanged. Scrambled siRNA was used as control.)
Testing Data
(Figure 10 KD Validation in HeLa cells (Horinaka et al., 2005)HeLa cells were transfected with DR4siRNA or LacZ control siRNA. At 24 h after transfection, the cells were treated with or without 20 ?M luteolin for 24 h. Western blot analysis was carried out with anti-DR4 antibodies (1139). DR4 expression was markedly reduced after DR4 knockdown.)
Testing Data
(Figure 10 KD Validation in HeLa cells (Horinaka et al., 2005)HeLa cells were transfected with DR4siRNA or LacZ control siRNA. At 24 h after transfection, the cells were treated with or without 20 ?M luteolin for 24 h. Western blot analysis was carried out with anti-DR4 antibodies (1139). DR4 expression was markedly reduced after DR4 knockdown.)
NCBI and Uniprot Product Information
NCBI Description
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. [provided by RefSeq, Jul 2008]
Uniprot Description
TRAIL-R1: Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF- kappa-B.
Protein type: Membrane protein, integral
Chromosomal Location of Human Ortholog: 8p21
Cellular Component: integral to membrane; plasma membrane
Molecular Function: protein binding; protease binding; death receptor activity; TRAIL binding; receptor activity; transcription factor binding
Biological Process: caspase activation; induction of apoptosis via death domain receptors; apoptosis; activation of NF-kappaB-inducing kinase; signal transduction
Research Articles on TNFRSF10A
Similar Products
Product Notes
The TNFRSF10A tnfrsf10a (Catalog #AAA151363) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The DR4 Antibody reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's DR4 can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Western Blot (WB), Immunocytochemistry (ICC). DR4 antibody can be used for detection of DR4 expression by Western blot at 0.5 mug/mL. Antibody can also be used for immunocytochemistry starting at 10 mug/mL. Knockdown (Knockout, KO validated) Antibody. Researchers should empirically determine the suitability of the TNFRSF10A tnfrsf10a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "DR4, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
